Mutations in apolipoprotein A-I (apoA-I) result in deposition of amyloid fibrils, predominantly in the liver, kidney and heart, and cause a rare, late-onset, autosomal dominant form of amyloidosis.

The most common nonfamilial forms of amyloidosis that involve the kidney are the AL (amyloid light chain) and AA (serum amyloid A) types. These two forms require different treatment strategies ...

Surgical excision of Castleman's disease. - Eprodisate slowed the decline of renal function in AA amyloidosis. - Currently under study: - Diflunisal, FX-1006 and doxycycline in ATTR amyloidosis.

However, only two related conditions are associated with the simultaneous presence of Bence Jones proteinuria and heavy albuminuria: renal AL amyloidosis and LCDD. [20] It is not uncommon for ...

AstraZeneca has licensed in an antisense drug from Ionis Pharmaceuticals to treat kidney disease in a deal ... the company is developing to treat TTR amyloidosis. Volanesorsen, an antisense ...

AstraZeneca (AZ) and Ionis Pharmaceuticals’ Wainzua (eplontersen) has been approved by the European Commission (EC) to treat ...